The goals of the structural biology core are threefold: (1) to determine structures of the HIV envelope glycoprotein in its various conformations (and especially in the unliganded state found on the surface of a mature virion), in order to have as complete a """"""""molecular movie"""""""" of its conformational transitions as possible; (2) to engage in collaborative structure determinations with investigators in the CHAVI project (in particular to answer questions about how molecular context influences immunogenicity of gp120 variable loops) or to help organize such collaborations with other laboratories when appropriate; (3) to communicate the complex picture of envelope conformational transformations to the rest of the HIV community and in particular to the other investigators in this CHAVI consortium.
Specific aims i nclude: (1) generating stabilized forms of unliganded HIV-1 gp120 for structural studies, by introducing disulfide bonds based on the recently determined structure of unliganded SIV gp120; (2) using the results of the first aim to produce stabilized gp140 trimers for structural studies; (3) using the results of the first two aims to analyze the immunogenic properties of the HIV envelope protein in its unliganded conformation. Depending on the outcome of other experiments in the CHAVI consortium, structures will be determined for certain Fab fragments from """"""""broadly"""""""" neutralizing mAbs, in complex with peptide antigens or with gp120 or gp140 bearing the appropriate epitopes. There will be an ongoing effort to communicate the complexities of envelope conformational changes, through development of an interactive molecular animation that incorporates new structural data as they emerge.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI067854-01
Application #
7127928
Study Section
Special Emphasis Panel (ZAI1-CL-A (M1))
Project Start
2005-07-14
Project End
2012-06-30
Budget Start
2005-07-14
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$671,750
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Prévost, Jérémie; Richard, Jonathan; Medjahed, Halima et al. (2018) Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol 92:
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Yates, Nicole L; deCamp, Allan C; Korber, Bette T et al. (2018) HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol 92:
Pardi, Norbert; Hogan, Michael J; Porter, Frederick W et al. (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17:261-279
Liu, Donglai; Wang, Chu; Hora, Bhavna et al. (2017) A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology 14:46
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323
Matoga, Mitch M; Hosseinipour, Mina C; Aga, Evgenia et al. (2017) Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. Antivir Ther 22:205-213

Showing the most recent 10 out of 309 publications